Regeneron Pharmaceuticals, Inc. REGN
788.04
(7.98)
(1.00%)
as of 25 Sep
- Market cap
- $81.3B
- P/E
- 18.8×
Follow REGN
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Regeneron Pharmaceuticals, Inc. (REGN) Debt to equity
Regeneron Pharmaceuticals, Inc.'s debt to equity at the end of the quarter to 30 June 2026 was 0.1×, down 0.0× from fiscal 2025 (0.1×). Over the past ten years it has ranged from 0.1× (fiscal 2019) to 0.2× (fiscal 2020); the current reading is higher than 36% of that period. That is above the Biotechnology industry median of 0.0× and above the Healthcare sector median of 0.0×.
Debt to equity, annual
Annual
| Period | Debt to equity | Change |
|---|---|---|
| FY2025 | 0.1× | (5.97%) |
| FY2024 | 0.1× | (11.53%) |
| FY2023 | 0.1× | (12.67%) |
| FY2022 | 0.1× | 12.99% |
| FY2021 | 0.1× | (56.85%) |
| FY2020 | 0.2× | 279.66% |
| FY2019 | 0.1× | (20.40%) |
| FY2018 | 0.1× | (29.34%) |
| FY2017 | 0.1× | 44.94% |
| FY2016 | 0.1× | (20.44%) |
Quarterly
| Period | Debt to equity | Change |
|---|---|---|
| Jun 2026 | 0.1× | (0.95%) |
| Mar 2026 | 0.1× | (27.02%) |
| Dec 2025 | 0.1× | (0.92%) |
| Sep 2025 | 0.1× | (3.32%) |
| 42 more quarters | Free account |
Against its own ten years
Low 0.1×
High 0.2×
Ten-year median
0.1×
Current reading's percentile
36
Debt to equity against peers
| Company | Debt to equity |
|---|---|
| VRTX Vertex Pharmaceuticals Incorporated compare | 0.0× |
| ARGX argenex SE compare | 0.0× |
| REGN Regeneron Pharmaceuticals, Inc. | 0.1× |
| MRNA Moderna, Inc. compare | 0.1× |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 0.2× |
| RVMD Revolution Medicines, Inc. compare | 0.4× |
| INSM Insmed, Inc. compare | 0.7× |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 0.7× |
| RPRX Royalty Pharma PLC compare | 0.9× |
| Biotechnology industry median | 0.0× |
| Healthcare sector median | 0.0× |
| Market median | 0.2× |
What Debt to equity is
Debt to Equity Ratio shows how much a company relies on borrowed money compared with the money its shareholders have in the business.
(Long Term Debt (Total) + Current Part of Debt) ÷ Shareholders Equity (Total)
More on REGN
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement